Deel uit Interview met lead manager van Artisan Global Opportunities fund in Barron's. Genmab is een van hun top 10 holdings, waar hij ook wat over zegt. Duidelijk dat hij naast grote potentie natuurlijk de altijd bijbehorende risico's ziet. Ik denk dat een 2e Genmab blockbuster dit verhaal tzt in heel ander daglicht zet. Ach ja, bekend verhaal in biotech: never a dull moment. En de Duobody technologie (licensies) blijf ik de dark horse vinden in positieve zin. Dit kan op termijn een grote additionele waarde creeren. Maar (zeker nu) nog minder aansprekend dan Darzalex...
Q: Trump’s promise to address high drug prices and dismantle Obamacare has put health-care stocks, especially drugmakers, in the doghouse. Yet a trio of health-care names – medical-device maker Boston Scientific (BSX), biotech giant Regeneron, and Danish drug maker Genmab (GEN.Denmark) -- are among your top 10 holdings. Why?
A: Innovation. Drugmakers and medical-device companies will still get paid for innovative therapies.
More From Barron’s
Chipotle: Can It Be Fixed?
Goldilocks Joins Team Trump
Brinker International Sets the Table for Growth at Chili’s
Q: What’s the best pick out of the three?
A: Boston Scientific is the steadiest, most consistent, and most predictable of the three, and therefore our largest health-care holding. Genmab’s stock dramatically outperformed Regeneron over the past year due to the blood-cancer drug Darzalex, which it licensed to Johnson & Johnson in 2012, and the setbacks suffered by Regeneron’s cholesterol drug Praluent. Genmab remains a possible moonshot that could double in value over the next five years, though a rich valuation makes it risky. Regeneron, meanwhile, is awaiting Federal Drug Administration approval for dupilumab, an experimental drug for atopic dermatitis that could get launched next year.